{"id":50187,"date":"2025-12-08T21:51:37","date_gmt":"2025-12-08T13:51:37","guid":{"rendered":"https:\/\/flcube.com\/?p=50187"},"modified":"2025-12-08T21:51:38","modified_gmt":"2025-12-08T13:51:38","slug":"asieris-apl-1401-ulcerative-colitis-phase-1b-data-positive","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=50187","title":{"rendered":"Asieris APL-1401 Ulcerative-Colitis Phase 1b Data Positive"},"content":{"rendered":"\n<p><strong>Asieris Pharmaceuticals<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688176:SHA\">SHA: 688176<\/a>) presented <strong>Phase 1b trial data<\/strong> for <strong>APL-1401<\/strong> in <strong>moderate-to-severe active ulcerative colitis (UC)<\/strong> at the 19th European Colorectal Congress (ECC\u202f2025). The orally administered <strong>dopamine beta-hydroxylase (DBH) inhibitor<\/strong> demonstrated a favorable safety profile and positive efficacy signals within a 4-week treatment period.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone-amp-data-presentation\">Regulatory Milestone &amp; Data Presentation<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Asieris Pharmaceuticals (688176.SH)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>APL-1401<\/td><\/tr><tr><td><strong>Data Presentation<\/strong><\/td><td>19th European Colorectal Congress (ECC\u202f2025)<\/td><\/tr><tr><td><strong>Trial Phase<\/strong><\/td><td>Phase 1b<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Moderate-to-severe active ulcerative colitis (UC)<\/td><\/tr><tr><td><strong>Administration<\/strong><\/td><td>Oral<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<p><strong>APL-1401<\/strong> is a <strong>potent and selective dopamine beta-hydroxylase (DBH) inhibitor<\/strong> with a novel mechanism for autoimmune diseases:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target<\/strong>: DBH, the sole enzyme catalyzing norepinephrine (NE) synthesis from dopamine (DA)<\/li>\n\n\n\n<li><strong>Mechanism<\/strong>: Inhibition elevates DA levels and decreases NE levels<\/li>\n\n\n\n<li><strong>Therapeutic Effect<\/strong>: Restores normal intestinal immune homeostasis<\/li>\n\n\n\n<li><strong>Innovation<\/strong>: First DBH inhibitor in clinical development for ulcerative colitis<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-phase-1b-clinical-results\">Phase 1b Clinical Results<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Result (120\u202fmg dose group)<\/th><th>Clinical Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>Safety Profile<\/strong><\/td><td>Overall favorable, <strong>no serious adverse events (SAEs)<\/strong><\/td><td>Well-tolerated, supports further development<\/td><\/tr><tr><td><strong>Clinical Response Rate<\/strong><\/td><td><strong>33.3%<\/strong> at 4 weeks<\/td><td>Positive signal in short treatment window<\/td><\/tr><tr><td><strong>Histological Improvement Rate<\/strong><\/td><td><strong>66.7%<\/strong> at 4 weeks<\/td><td>Strong tissue-level response suggests disease modification potential<\/td><\/tr><tr><td><strong>Treatment Duration<\/strong><\/td><td>4-week cycle<\/td><td>Rapid onset of action vs. traditional UC therapies<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-strategic-outlook\">Market Context &amp; Strategic Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Ulcerative Colitis Market<\/strong>: China UC prevalence exceeds 400,000 patients; market projected <strong>\u00a58\u202fbillion<\/strong> by 2030<\/li>\n\n\n\n<li><strong>Unmet Need<\/strong>: Limited oral options beyond 5-ASA, corticosteroids, and JAK inhibitors; DBH mechanism offers novel pathway<\/li>\n\n\n\n<li><strong>Competitive Landscape<\/strong>: Dominated by anti-TNF agents (Humira, Remicade) and emerging JAK inhibitors; APL-1401 provides differentiated mechanism<\/li>\n\n\n\n<li><strong>Development Path<\/strong>: Phase 2 trial planned for Q2\u202f2026; potential for accelerated approval based on histological improvement data<\/li>\n\n\n\n<li><strong>Global Potential<\/strong>: DBH inhibition may be applicable to other autoimmune diseases (Crohn&#8217;s, rheumatoid arthritis)<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding APL-1401 development timelines, clinical outcomes, and market potential. Actual results may differ due to clinical, regulatory, and competitive uncertainties.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/688176_20251204_0VF2.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688176_20251204_0VF2.\"><\/object><a id=\"wp-block-file--media-039aea78-7102-4de9-ac6b-fd23efae591c\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/688176_20251204_0VF2.pdf\">688176_20251204_0VF2<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/688176_20251204_0VF2.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-039aea78-7102-4de9-ac6b-fd23efae591c\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Asieris Pharmaceuticals (SHA: 688176) presented Phase 1b trial data for APL-1401 in moderate-to-severe active ulcerative&#8230;<\/p>\n","protected":false},"author":1,"featured_media":50188,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[106,316,17,1127],"class_list":["post-50187","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-academic-conference","tag-asieris-pharmaceuticals","tag-clinical-trial-results","tag-sha-688176"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Asieris APL-1401 Ulcerative-Colitis Phase 1b Data Positive - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Asieris Pharmaceuticals (SHA: 688176) presented Phase 1b trial data for APL-1401 in moderate-to-severe active ulcerative colitis (UC) at the 19th European Colorectal Congress (ECC\u202f2025). The orally administered dopamine beta-hydroxylase (DBH) inhibitor demonstrated a favorable safety profile and positive efficacy signals within a 4-week treatment period.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=50187\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Asieris APL-1401 Ulcerative-Colitis Phase 1b Data Positive\" \/>\n<meta property=\"og:description\" content=\"Asieris Pharmaceuticals (SHA: 688176) presented Phase 1b trial data for APL-1401 in moderate-to-severe active ulcerative colitis (UC) at the 19th European Colorectal Congress (ECC\u202f2025). The orally administered dopamine beta-hydroxylase (DBH) inhibitor demonstrated a favorable safety profile and positive efficacy signals within a 4-week treatment period.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=50187\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-08T13:51:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-08T13:51:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0809.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50187#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50187\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Asieris APL-1401 Ulcerative-Colitis Phase 1b Data Positive\",\"datePublished\":\"2025-12-08T13:51:37+00:00\",\"dateModified\":\"2025-12-08T13:51:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50187\"},\"wordCount\":318,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50187#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0809.webp\",\"keywords\":[\"Academic conference\",\"Asieris Pharmaceuticals\",\"Clinical trial results\",\"SHA: 688176\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50187#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50187\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=50187\",\"name\":\"Asieris APL-1401 Ulcerative-Colitis Phase 1b Data Positive - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50187#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50187#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0809.webp\",\"datePublished\":\"2025-12-08T13:51:37+00:00\",\"dateModified\":\"2025-12-08T13:51:38+00:00\",\"description\":\"Asieris Pharmaceuticals (SHA: 688176) presented Phase 1b trial data for APL-1401 in moderate-to-severe active ulcerative colitis (UC) at the 19th European Colorectal Congress (ECC\u202f2025). The orally administered dopamine beta-hydroxylase (DBH) inhibitor demonstrated a favorable safety profile and positive efficacy signals within a 4-week treatment period.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50187#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50187\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50187#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0809.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0809.webp\",\"width\":1080,\"height\":608,\"caption\":\"Asieris APL-1401 Ulcerative-Colitis Phase 1b Data Positive\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50187#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Asieris APL-1401 Ulcerative-Colitis Phase 1b Data Positive\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Asieris APL-1401 Ulcerative-Colitis Phase 1b Data Positive - Insight, China&#039;s Pharmaceutical Industry","description":"Asieris Pharmaceuticals (SHA: 688176) presented Phase 1b trial data for APL-1401 in moderate-to-severe active ulcerative colitis (UC) at the 19th European Colorectal Congress (ECC\u202f2025). The orally administered dopamine beta-hydroxylase (DBH) inhibitor demonstrated a favorable safety profile and positive efficacy signals within a 4-week treatment period.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=50187","og_locale":"en_US","og_type":"article","og_title":"Asieris APL-1401 Ulcerative-Colitis Phase 1b Data Positive","og_description":"Asieris Pharmaceuticals (SHA: 688176) presented Phase 1b trial data for APL-1401 in moderate-to-severe active ulcerative colitis (UC) at the 19th European Colorectal Congress (ECC\u202f2025). The orally administered dopamine beta-hydroxylase (DBH) inhibitor demonstrated a favorable safety profile and positive efficacy signals within a 4-week treatment period.","og_url":"https:\/\/flcube.com\/?p=50187","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-08T13:51:37+00:00","article_modified_time":"2025-12-08T13:51:38+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0809.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=50187#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=50187"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Asieris APL-1401 Ulcerative-Colitis Phase 1b Data Positive","datePublished":"2025-12-08T13:51:37+00:00","dateModified":"2025-12-08T13:51:38+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=50187"},"wordCount":318,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=50187#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0809.webp","keywords":["Academic conference","Asieris Pharmaceuticals","Clinical trial results","SHA: 688176"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=50187#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=50187","url":"https:\/\/flcube.com\/?p=50187","name":"Asieris APL-1401 Ulcerative-Colitis Phase 1b Data Positive - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=50187#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=50187#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0809.webp","datePublished":"2025-12-08T13:51:37+00:00","dateModified":"2025-12-08T13:51:38+00:00","description":"Asieris Pharmaceuticals (SHA: 688176) presented Phase 1b trial data for APL-1401 in moderate-to-severe active ulcerative colitis (UC) at the 19th European Colorectal Congress (ECC\u202f2025). The orally administered dopamine beta-hydroxylase (DBH) inhibitor demonstrated a favorable safety profile and positive efficacy signals within a 4-week treatment period.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=50187#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=50187"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=50187#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0809.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0809.webp","width":1080,"height":608,"caption":"Asieris APL-1401 Ulcerative-Colitis Phase 1b Data Positive"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=50187#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Asieris APL-1401 Ulcerative-Colitis Phase 1b Data Positive"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0809.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50187","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=50187"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50187\/revisions"}],"predecessor-version":[{"id":50190,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50187\/revisions\/50190"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/50188"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=50187"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=50187"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=50187"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}